Viemed Healthcare (VMD) Competitors

$9.65 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$9.52 -0.13 (-1.30%)

As of 05/22/2026 06:24 PM Eastern

VMD vs. TDOC, PNTG, WGS, CDNA, and INNV

Should you buy Viemed Healthcare stock or one of its competitors? MarketBeat compares Viemed Healthcare with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Viemed Healthcare include Teladoc Health (TDOC), The Pennant Group (PNTG), GeneDx (WGS), CareDx (CDNA), and InnovAge (INNV). These companies are all part of the "healthcare" industry.

How does Viemed Healthcare compare to Teladoc Health?

Teladoc Health (NYSE:TDOC) and Viemed Healthcare (NASDAQ:VMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Teladoc Health has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, Viemed Healthcare has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

Viemed Healthcare has lower revenue, but higher earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teladoc Health	$2.53B	0.47	-$200.32M	-$0.97	N/A
Viemed Healthcare	$270.28M	1.37	$14.93M	$0.37	26.08

In the previous week, Teladoc Health had 8 more articles in the media than Viemed Healthcare. MarketBeat recorded 8 mentions for Teladoc Health and 0 mentions for Viemed Healthcare. Teladoc Health's average media sentiment score of 0.89 beat Viemed Healthcare's score of 0.00 indicating that Teladoc Health is being referred to more favorably in the media.

Company	Overall Sentiment
Teladoc Health	Positive
Viemed Healthcare	Neutral

Teladoc Health currently has a consensus price target of $7.53, indicating a potential upside of 14.37%. Given Teladoc Health's stronger consensus rating and higher probable upside, equities analysts plainly believe Teladoc Health is more favorable than Viemed Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teladoc Health	1 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.22
Viemed Healthcare	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

76.8% of Teladoc Health shares are owned by institutional investors. Comparatively, 74.2% of Viemed Healthcare shares are owned by institutional investors. 0.7% of Teladoc Health shares are owned by insiders. Comparatively, 20.0% of Viemed Healthcare shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Viemed Healthcare has a net margin of 5.20% compared to Teladoc Health's net margin of -6.81%. Viemed Healthcare's return on equity of 10.52% beat Teladoc Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teladoc Health	-6.81%	-11.45%	-5.54%
Viemed Healthcare	5.20%	10.52%	7.60%

Summary

Teladoc Health and Viemed Healthcare tied by winning 8 of the 16 factors compared between the two stocks.

How does Viemed Healthcare compare to The Pennant Group?

The Pennant Group (NASDAQ:PNTG) and Viemed Healthcare (NASDAQ:VMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

In the previous week, The Pennant Group had 1 more articles in the media than Viemed Healthcare. MarketBeat recorded 1 mentions for The Pennant Group and 0 mentions for Viemed Healthcare. The Pennant Group's average media sentiment score of 0.60 beat Viemed Healthcare's score of 0.00 indicating that The Pennant Group is being referred to more favorably in the media.

Company	Overall Sentiment
The Pennant Group	Positive
Viemed Healthcare	Neutral

The Pennant Group currently has a consensus target price of $39.00, suggesting a potential upside of 14.98%. Given The Pennant Group's stronger consensus rating and higher probable upside, equities analysts clearly believe The Pennant Group is more favorable than Viemed Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
The Pennant Group	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Viemed Healthcare	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

The Pennant Group has higher revenue and earnings than Viemed Healthcare. Viemed Healthcare is trading at a lower price-to-earnings ratio than The Pennant Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
The Pennant Group	$947.71M	1.24	$29.58M	$0.85	39.91
Viemed Healthcare	$270.28M	1.37	$14.93M	$0.37	26.08

The Pennant Group has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market. Comparatively, Viemed Healthcare has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

85.9% of The Pennant Group shares are owned by institutional investors. Comparatively, 74.2% of Viemed Healthcare shares are owned by institutional investors. 6.9% of The Pennant Group shares are owned by company insiders. Comparatively, 20.0% of Viemed Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Viemed Healthcare has a net margin of 5.20% compared to The Pennant Group's net margin of 2.96%. Viemed Healthcare's return on equity of 10.52% beat The Pennant Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
The Pennant Group	2.96%	10.07%	4.23%
Viemed Healthcare	5.20%	10.52%	7.60%

Summary

The Pennant Group beats Viemed Healthcare on 11 of the 16 factors compared between the two stocks.

How does Viemed Healthcare compare to GeneDx?

GeneDx (NASDAQ:WGS) and Viemed Healthcare (NASDAQ:VMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

Viemed Healthcare has a net margin of 5.20% compared to GeneDx's net margin of -17.58%. Viemed Healthcare's return on equity of 10.52% beat GeneDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-17.58%	9.15%	5.21%
Viemed Healthcare	5.20%	10.52%	7.60%

Viemed Healthcare has lower revenue, but higher earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	3.29	-$21.02M	-$2.68	N/A
Viemed Healthcare	$270.28M	1.37	$14.93M	$0.37	26.08

GeneDx has a beta of 2.06, indicating that its share price is 106% more volatile than the broader market. Comparatively, Viemed Healthcare has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

GeneDx currently has a consensus target price of $96.43, suggesting a potential upside of 103.82%. Given GeneDx's stronger consensus rating and higher probable upside, equities analysts clearly believe GeneDx is more favorable than Viemed Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Viemed Healthcare	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, GeneDx had 17 more articles in the media than Viemed Healthcare. MarketBeat recorded 17 mentions for GeneDx and 0 mentions for Viemed Healthcare. GeneDx's average media sentiment score of 0.70 beat Viemed Healthcare's score of 0.00 indicating that GeneDx is being referred to more favorably in the media.

Company	Overall Sentiment
GeneDx	Positive
Viemed Healthcare	Neutral

61.7% of GeneDx shares are owned by institutional investors. Comparatively, 74.2% of Viemed Healthcare shares are owned by institutional investors. 29.6% of GeneDx shares are owned by insiders. Comparatively, 20.0% of Viemed Healthcare shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

GeneDx beats Viemed Healthcare on 9 of the 16 factors compared between the two stocks.

How does Viemed Healthcare compare to CareDx?

CareDx (NASDAQ:CDNA) and Viemed Healthcare (NASDAQ:VMD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

In the previous week, CareDx had 2 more articles in the media than Viemed Healthcare. MarketBeat recorded 2 mentions for CareDx and 0 mentions for Viemed Healthcare. CareDx's average media sentiment score of 0.00 equaled Viemed Healthcare'saverage media sentiment score.

Company	Overall Sentiment
CareDx	Neutral
Viemed Healthcare	Neutral

CareDx has a beta of 2.49, indicating that its share price is 149% more volatile than the broader market. Comparatively, Viemed Healthcare has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

74.2% of Viemed Healthcare shares are owned by institutional investors. 4.4% of CareDx shares are owned by company insiders. Comparatively, 20.0% of Viemed Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

CareDx presently has a consensus price target of $25.00, suggesting a potential upside of 15.58%. Given CareDx's higher possible upside, equities research analysts plainly believe CareDx is more favorable than Viemed Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CareDx	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Viemed Healthcare	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Viemed Healthcare has a net margin of 5.20% compared to CareDx's net margin of -2.01%. Viemed Healthcare's return on equity of 10.52% beat CareDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CareDx	-2.01%	-2.65%	-1.96%
Viemed Healthcare	5.20%	10.52%	7.60%

Viemed Healthcare has lower revenue, but higher earnings than CareDx. CareDx is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CareDx	$379.80M	2.94	-$21.35M	-$0.16	N/A
Viemed Healthcare	$270.28M	1.37	$14.93M	$0.37	26.08

Summary

Viemed Healthcare beats CareDx on 8 of the 14 factors compared between the two stocks.

How does Viemed Healthcare compare to InnovAge?

Viemed Healthcare (NASDAQ:VMD) and InnovAge (NASDAQ:INNV) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

Viemed Healthcare has higher earnings, but lower revenue than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viemed Healthcare	$270.28M	1.37	$14.93M	$0.37	26.08
InnovAge	$853.70M	1.14	-$30.31M	-$0.09	N/A

Viemed Healthcare has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, InnovAge has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market.

InnovAge has a consensus price target of $7.00, suggesting a potential downside of 2.78%. Given InnovAge's higher probable upside, analysts plainly believe InnovAge is more favorable than Viemed Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viemed Healthcare	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
InnovAge	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

Viemed Healthcare has a net margin of 5.20% compared to InnovAge's net margin of -1.22%. Viemed Healthcare's return on equity of 10.52% beat InnovAge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viemed Healthcare	5.20%	10.52%	7.60%
InnovAge	-1.22%	-4.73%	-2.20%

74.2% of Viemed Healthcare shares are held by institutional investors. Comparatively, 12.3% of InnovAge shares are held by institutional investors. 20.0% of Viemed Healthcare shares are held by insiders. Comparatively, 1.0% of InnovAge shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, InnovAge's average media sentiment score of 0.76 beat Viemed Healthcare's score of 0.00 indicating that InnovAge is being referred to more favorably in the news media.

Company	Overall Sentiment
Viemed Healthcare	Neutral
InnovAge	Positive

Summary

Viemed Healthcare beats InnovAge on 11 of the 14 factors compared between the two stocks.

Get Viemed Healthcare News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VMD vs. The Competition

Export

Metric	Viemed Healthcare	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$369.95M	$8.52B	$6.46B	$12.34B
Dividend Yield	N/A	2.50%	2.76%	5.28%
P/E Ratio	26.08	16.24	21.22	25.66
Price / Sales	1.37	8.28	562.28	86.31
Price / Cash	8.38	17.11	43.49	56.67
Price / Book	2.54	4.06	10.31	7.14
Net Income	$14.93M	$224.05M	$3.57B	$335.98M
7 Day Performance	0.42%	5.34%	6.43%	4.15%
1 Month Performance	-0.10%	-0.08%	3.57%	2.54%
1 Year Performance	50.31%	0.98%	34.07%	35.06%

Viemed Healthcare Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VMD Viemed Healthcare	1.5778 of 5 stars	$9.65 flat	N/A	+50.3%	$369.95M	$270.28M	26.08	1,382
TDOC Teladoc Health	3.2467 of 5 stars	$6.76 -2.4%	$7.53 +11.5%	-3.4%	$1.25B	$2.53B	N/A	5,600
PNTG The Pennant Group	3.6531 of 5 stars	$35.42 +3.8%	$39.00 +10.1%	+22.1%	$1.19B	$947.71M	41.67	9,700	Gap Up
WGS GeneDx	4.3036 of 5 stars	$39.49 -0.3%	$96.43 +144.2%	-33.9%	$1.18B	$427.54M	N/A	1,300	Gap Up
CDNA CareDx	1.6545 of 5 stars	$21.40 -0.7%	$25.00 +16.8%	+27.6%	$1.11B	$379.80M	N/A	740

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VMD) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viemed Healthcare (VMD) Competitors

VMD vs. TDOC, PNTG, WGS, CDNA, and INNV

How does Viemed Healthcare compare to Teladoc Health?

Summary

How does Viemed Healthcare compare to The Pennant Group?

Summary

How does Viemed Healthcare compare to GeneDx?

Summary

How does Viemed Healthcare compare to CareDx?

Summary

How does Viemed Healthcare compare to InnovAge?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VMD vs. The Competition

Viemed Healthcare Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viemed Healthcare (VMD) Competitors

VMD vs. TDOC, PNTG, WGS, CDNA, and INNV

How does Viemed Healthcare compare to Teladoc Health?

Which has more risk & volatility, TDOC or VMD?

Which has better earnings and valuation, TDOC or VMD?

Does the media prefer TDOC or VMD?

Do analysts recommend TDOC or VMD?

Do insiders and institutionals have more ownership in TDOC or VMD?

Is TDOC or VMD more profitable?

Summary

How does Viemed Healthcare compare to The Pennant Group?

Does the media prefer PNTG or VMD?

Do analysts rate PNTG or VMD?

Which has better earnings & valuation, PNTG or VMD?

Which has more risk & volatility, PNTG or VMD?

Do institutionals and insiders hold more shares of PNTG or VMD?

Is PNTG or VMD more profitable?

Summary

How does Viemed Healthcare compare to GeneDx?

Is WGS or VMD more profitable?

Which has higher earnings and valuation, WGS or VMD?

Which has more risk & volatility, WGS or VMD?

Do analysts prefer WGS or VMD?

Does the media refer more to WGS or VMD?

Do institutionals & insiders hold more shares of WGS or VMD?

Summary

How does Viemed Healthcare compare to CareDx?

Does the media prefer CDNA or VMD?

Which has more volatility & risk, CDNA or VMD?

Do insiders & institutionals hold more shares of CDNA or VMD?

Do analysts prefer CDNA or VMD?

Is CDNA or VMD more profitable?

Which has preferable valuation and earnings, CDNA or VMD?

Summary

How does Viemed Healthcare compare to InnovAge?

Which has higher earnings & valuation, VMD or INNV?

Which has more risk and volatility, VMD or INNV?

Do analysts recommend VMD or INNV?

Is VMD or INNV more profitable?

Do institutionals & insiders hold more shares of VMD or INNV?

Does the media favor VMD or INNV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VMD vs. The Competition

Viemed Healthcare Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools